Cell-Mediated Immune Responses After Administration of the Live or the Recombinant Zoster Vaccine: 5-Year Persistence

J Infect Dis. 2022 Apr 19;225(8):1477-1481. doi: 10.1093/infdis/jiab580.

Abstract

We compared glycoprotein E (gE)- and varicella zoster virus (VZV)-specific Th1 immunity in 160 adults, aged 50-85 years, randomized to receive live or recombinant zoster vaccine (RZV). gE-specific responses measured by interferon-γ (IFN-γ) and interleukin 2 (IL-2) dual-color Fluorospot were significantly higher at all time points postimmunization in RZV recipients. VZV-specific IL-2+ memory, but not IFN-γ+ or IFN-γ+IL-2+ effector responses, were higher in RZV recipients at ≥3 months postimmunization. Only RZV recipients maintained higher postvaccination gE-specific IL-2+ and IFN-γ+ and VZV-specific IL-2+ responses for 5 years. The 5-year persistence of VZV-specific memory and gE-specific Th1 immunity may underlie superior RZV efficacy. Clinical Trials Registration NCT02114333.

Keywords: immune responses; immunogenicity; old adults; recombinant zoster vaccine; zoster vaccine live.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Herpes Zoster Vaccine*
  • Herpes Zoster* / prevention & control
  • Herpesvirus 3, Human
  • Humans
  • Immunity, Cellular
  • Interferon-gamma
  • Interleukin-2
  • Middle Aged
  • Vaccines, Synthetic

Substances

  • Herpes Zoster Vaccine
  • Interleukin-2
  • Vaccines, Synthetic
  • Interferon-gamma

Associated data

  • ClinicalTrials.gov/NCT02114333